Thanks to Qingxi (Tim) Jia for his help drafting this edition of the CBB!
China’s Covid-19 Vaccine Rollout Update
I. Approval Status for the main 2 vaccines (NY Times):
Sinopharm approved in:
China, U.A.E., Bahrain
Egypt (emergency-use)
Sinovac has limited use in China
II. List of countries which ordered Chinese vaccines (SupChina)
- Pakistan, Hungary, Ukraine, UAE, Bahrain, Egypt, Morocco, Indonesia, Thailand, Philippines, Brazil, Peru
- Thailand imports 2 million Sinovac doses (Fortune)
- Indonesia: imports 3 million Sinovac doses, received supplies to locally produce more (Fortune)
- Pakistan: buys 1.2 million doses (Yahoo News)
- Peru: buys 38 million doses (VoA)
Released Sinopharm Phase 3 Efficacy: roughly 79%, as per NY Times. Brazil has claimed results put it closer to 50%, however, according to BBC. Compare to Moderna, Pfizer, and Sputnik’s claimed efficacy rates of over 90%.
II. Vaccine Pricing:
- Based on prior individual accounts, two-dose vaccine costs roughly $60-$150 - SinoVac charging $30/dose (NY Times)
- Sinopharm charging less than $75/dose
- Zheng YiXin, deputy minister of National Health Commission states that the vaccine would be provided to the Chinese public for free.
III. Vaccine Production:
- 18 vaccine makers in China are ramping production (SCMP)
- Health officials say that China manufactured 610 million doses by 2020, and can reach 1 billion doses in 2021. (AP)
- SinoVac raises $515 million to double vaccine production (ChinaBioToday)
- China aims to vaccinate 50 million by mid-February (NY Times)